Clinical findings for residents near a polyurethane foam manufacturing plant

Archives of Environmental Health

Volumn 57, Issue 3, 2002, Pages 239-246

  Darcey, Dennis ^a   Lipscomb, Hester J ^a   Epling, Carol ^a   Pate, William ^b   Cherry, Lorene P ^b   Bernstein, Jonathan ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Air emissions; Fiber processing; Manufacturing plant; Methacholine; Polyurethane foam; Toluene diisocyanate

Indexed keywords

ANTIBODY; ISOCYANIC ACID DERIVATIVE; METHACHOLINE; POLYURETHAN FOAM;

ADULT; AGED; AIR POLLUTION; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; DYSPNEA; ENVIRONMENTAL EXPOSURE; FEMALE; HEADACHE; HUMAN; MALE; MUCOSA INFLAMMATION; ODOR; PRIORITY JOURNAL; SENSITIZATION; THORAX PAIN; WHEEZING;

BRONCHUS;

EID: 0036589788     PISSN: 00039896     EISSN: None     Source Type: Journal    
DOI: 10.1080/00039890209602943     Document Type: Article

References (29)

1. North Carolina Division of Air Quality (NCDAQ). Raleigh, NC: Investigation 95007, 1995.
2. North Carolina Division of Air Quality (NCDAQ). Summary of Toxicity Assessment of Toluene Diisocyanate. Raleigh, NC: NCDAQ, Scientific Advisory Board on Toxic Air Pollutants; 1999.
3. American College of Government Industrial Hygienists (ACGIH), 1997 TLV's and SB's. Cincinnati, OH: ACGIH Publications, 1997.
4. North Carolina Division of Air Quality (NCDAQ). Summary of Toxicity Assessment of Methylene Chloride. Raleigh, NC: NCDAQ, Scientific Advisory Board on Toxic Air Pollutants; 1999.
5. Agency for Toxic Substances and Disease Registry. Community exposure to toluene diisocyanate. Hazard Substances and Public Health Spring 1998; 8(1):1-3.
6. Community exposure to toluene diisocyanate from a polyurethane manufacturing plant in North Carolina [editoral]. Mor Mortal Wkly Rep 12 June 1998; 27(22):455-457.
7. Orloff KG, Batts-Osborne D, Kilgus T, et al. Antibodies to toluene di isocyanate in an environmentally exposed population. Environ Health Perspect October 1998; 106(10):665-666.
8. Ferris BG. Epidemiology standardization project. Am Rev Respir Dis 1978; 118:1-53.
9. Burney PGJ, Chin S. Developing a new questionnaire for measuring the prevalence and distribution of asthma. Chest 1987; 91 (suppl):79S—83S.
10. Granella F, D'Alessandro R, Manzoni GC, et al. International Headache Society classification: interobserver reliability in the diagnosis of primary headaches. Cephalalgia February 1994; 14 (1):16-20.
11. Kohler T, Eisentraut R, Graeber E. Headache classification based on questionnaire data: which symptoms are especially suitable? J Clin Epidemiol 1995; 48(6):797-803.
12. Chan-Yeung M. Occupational asthma. Chest November 1990; 98(Suppl):148S-161S.
13. Reilly MJ, Rosenman KD, Watt F, et al. Surveillance for occupational asthma Michigan and New Jersey, 1988-1992. Mor Mortal Wkly Rep 10 June 1994; 43(No. SS-1):9-17.
14. Meredith SK, Taylor VM, McDonald JC. Occupational respiratory disease in the U.K. 1989: a report to the British Thoracic Society of Occupational Medicine: The SWORD project group. Br J Ind Med 1991;48:292-298.
15. American Thoracic Society Committee on Proficiency Standards for Pulmonary Function Laboratories, Standardization of spirometry—1987 update. Am Rev Respir Dis 1987; 136:1285-1298.
16. American Thoracic Society DLCO Standardization Conference. Single breath carbon monoxide diffusing capacity (transfer factor): Recommendations for a standard technique. Am Rev Respir Dis 1987; 136:1299-1307.
17. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664.
18. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123:185-190.
19. Ruppel GE. Manual of Pulmonary Function Testing, 6th ed. Saint Louis, MO: Mosby Yearbook, 1994, pp 193-198.
20. Bernstein DI, Jolly A. Current diagnostic methods for diisocyanate-induced occupational asthma. Am J Ind Med 1999; 36: 459-468.
21. Lushniak BD, Reh CM, Bernstein DI, et al. Indirect assessment of 4, 4-diphenyl-methane diisocyanate (MDI) exposure by evaluation of specific humoral immune responses to MDI conjugated to human serum albumin (HSA). Am J Ind Med 1998; 33:471-477.
22. Bernstein DL, Korbee L, Stauder T, et al. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates. J Allergy Clin Immunol 1993; 92: 387-396.
23. Meggs WJ, Elsheik T, Metzger WJ, et al. Nasal pathology and ultrastructure in patients with chronic airway inflammation (RADS and RUDS) following an irritant exposure. J Toxicol Clin Toxicol 1996; 34(4):383-396.
24. Selden AL, Beilin L, Wass U. Isocyanate exposure and hypersensitivity pneumonitis—report of a probable case and prevalence of specific immunoglobulin G antibodies among exposed individuals. Scand J Work Environ Health 1989; 15:234-237.
25. Keskinen H, Tupasela O, Tikkainen U, et al. Experiences of specific IgE in asthma due to diisocyanates. Clin Allergy Immunol 1988; 18:597-604.
26. Bauer X, Marek W, Ammon J, et al. Respiratory and other hazards of isocyanates. Int Arch Occup Environ Health 1994; 66:141-152.
27. Bernstein JA. Overview of diisocyanate occupational asthma. Toxicology 1996; 111:181-189.
28. American College of Governmental Industrial Hygienists (ACGIH). Documentation of the Threshold Llimit Value and Biological Eposure Index for Toluene-2, 4-Diisocyanate, 6th ed. Cincinnati, OH: ACGIH Publications, 1991; 2:1587.
29. Kennedy AL, Brown WE. Isocyanates and lung disease: experimental approaches to molecular mechanisms. Occup Med April-june 1992; 7(2):301-329.